CTLA4 and Miyoshi myopathy: Combination anti-PD-1/anti-CTLA-4 treatment has strong phase III data supporting improved OS [121] and is optimal for treatment of brain metastases which are frequent in MM [122]; as such, combination anti-PD-1/anti-CTLA-4 forms standard-of-care treatment.